Long-term Extension of RECOVER- Long-term Effect of the 24h Transdermal Delivery of Rotigotine in Subjects With Idiopathic Parkinson's Disease

UCB

Status and phase: Terminated; Phase 3

Conditions: Parkinson's Disease

Treatments: Drug: Rotigotine

Study type: Interventional

Funder types: Industry

Identifiers

NCT00519532

SP0915

EudraCT number: 2006-006907-35 (Other Identifier)

Details and patient eligibility

About

The objective of this open-label extension is to assess the long-term effect of the 24-hour transdermal delivery of rotigotine on motor function, sleep quality, and nocturnal and non-motor symptoms of Parkinson's disease. The long-term safety and tolerability of the rotigotine transdermal patch will also be evaluated.

Enrollment: 84 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Completion of trial SP889

Exclusion criteria

• Ongoing serious adverse event assessed as related to trial medication

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

84 participants in 1 patient group

Rotigotine

Experimental group

Description:

Rotigotine Transdermal Patch

Treatment:

Drug: Rotigotine